Alpha Cognition Inc (ACOG) - Total Assets
Based on the latest financial reports, Alpha Cognition Inc (ACOG) holds total assets worth $46.30 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See shareholders equity of Alpha Cognition Inc for net asset value and shareholders' equity analysis.
Alpha Cognition Inc - Total Assets Trend (2020–2024)
This chart illustrates how Alpha Cognition Inc's total assets have evolved over time, based on quarterly financial data.
Alpha Cognition Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Alpha Cognition Inc's total assets of $46.30 Million consist of 99.0% current assets and 1.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 95.7% |
| Accounts Receivable | $253.43K | 0.5% |
| Inventory | $615.13K | 1.2% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $412.97K | 0.8% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2020–2024)
This chart illustrates how Alpha Cognition Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Alpha Cognition Inc (ACOG) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Alpha Cognition Inc's current assets represent 99.0% of total assets in 2024, an increase from 91.3% in 2020.
- Cash Position: Cash and equivalents constituted 95.7% of total assets in 2024, up from 70.3% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 8.0% in 2020.
- Asset Diversification: The largest asset category is inventory at 1.2% of total assets.
Alpha Cognition Inc Competitors by Total Assets
Key competitors of Alpha Cognition Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Alpha Cognition Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.69 | 1.50 | 2.15 |
| Quick Ratio | 6.03 | 1.50 | 2.15 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $38.87 Million | $1.51 Million | $4.12 Million |
Alpha Cognition Inc - Advanced Valuation Insights
This section examines the relationship between Alpha Cognition Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.13 |
| Latest Market Cap to Assets Ratio | 2.51 |
| Asset Growth Rate (YoY) | 1969.1% |
| Total Assets | $50.74 Million |
| Market Capitalization | $127.19 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Alpha Cognition Inc's assets at a significant premium (2.51x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Alpha Cognition Inc's assets grew by 1969.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Alpha Cognition Inc (2020–2024)
The table below shows the annual total assets of Alpha Cognition Inc from 2020 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $50.74 Million | +1969.06% |
| 2023-12-31 | $2.45 Million | -16.90% |
| 2022-12-31 | $2.95 Million | -77.09% |
| 2021-12-31 | $12.88 Million | +52.68% |
| 2020-12-31 | $8.44 Million | -- |
About Alpha Cognition Inc
Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatm… Read more